Shah NJ - Search Results

1

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.

Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, Adams S, Marafelias M, Ayyagari L, Gill SK, Ma B, Zaemes JP, Della Pia A, Alaoui A, Madhavan S, Belouali A, Pecora A, Ahn J, Atkins MB, Shah NJ. Lev-Ari S, et al. Among authors: shah nj. Cancer. 2023 Jun 15;129(12):1885-1894. doi: 10.1002/cncr.34742. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951119

2

A case of checkpoint inhibitor-induced celiac disease.

Alsaadi D, Shah NJ, Charabaty A, Atkins MB. Alsaadi D, et al. Among authors: shah nj. J Immunother Cancer. 2019 Aug 5;7(1):203. doi: 10.1186/s40425-019-0694-x. J Immunother Cancer. 2019. PMID: 31383006 Free PMC article.

3

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.

Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Shah NJ, et al. J Immunother Cancer. 2019 Dec 17;7(1):353. doi: 10.1186/s40425-019-0771-1. J Immunother Cancer. 2019. PMID: 31847881 Free PMC article.

4

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. Gul A, et al. Among authors: shah nj. J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3. J Clin Oncol. 2020. PMID: 32491962 Free PMC article.

5

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

Beattie J, Rizvi H, Fuentes P, Luo J, Schoenfeld A, Lin IH, Postow M, Callahan M, Voss MH, Shah NJ, Betof Warner A, Chawla M, Hellmann MD. Beattie J, et al. Among authors: shah nj. J Immunother Cancer. 2021 Feb;9(2):e001884. doi: 10.1136/jitc-2020-001884. J Immunother Cancer. 2021. PMID: 33568350 Free PMC article.

6

Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning.

Gupta S, Belouali A, Shah NJ, Atkins MB, Madhavan S. Gupta S, et al. Among authors: shah nj. JCO Clin Cancer Inform. 2021 May;5:541-549. doi: 10.1200/CCI.20.00109. JCO Clin Cancer Inform. 2021. PMID: 33989017 Free PMC article.

7

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.

Gibney GT, Zaemes J, Shand S, Shah NJ, Swoboda D, Gardner K, Radfar A, Petronic-Rosic V, Reilly MJ, Al-Refaie WB, Rapisuwon S, Atkins MB. Gibney GT, et al. Among authors: shah nj. J Immunother Cancer. 2021 Oct;9(10):e002955. doi: 10.1136/jitc-2021-002955. J Immunother Cancer. 2021. PMID: 34599027 Free PMC article.

8

Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.

Zhang D, Shah NJ, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. Zhang D, et al. Among authors: shah nj. Cancers (Basel). 2021 Dec 3;13(23):6109. doi: 10.3390/cancers13236109. Cancers (Basel). 2021. PMID: 34885219 Free PMC article.

9

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.

Shah NJ, Patel VG, Zhong X, Pina L, Hawley JE, Lin E, Gartrell BA, Febles VA, Wise DR, Qin Q, Mellgard G, Joshi H, Nauseef JT, Green DA, Vlachostergios PJ, Kwon DH, Huang F, Liaw B, Tagawa S, Kantoff P, Morris MJ, Oh WK. Shah NJ, et al. JNCI Cancer Spectr. 2022 May 2;6(3):pkac035. doi: 10.1093/jncics/pkac035. JNCI Cancer Spectr. 2022. PMID: 35657341 Free PMC article.

10

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids.

Shah NJ, Cook MR, Wu T, Lev-Ari S, Blackburn MJ, Serzan MT, Alaoui A, Ahn J, Atkins MB. Shah NJ, et al. J Natl Compr Canc Netw. 2022 Jul;20(7):800-807.e1. doi: 10.6004/jnccn.2022.7020. J Natl Compr Canc Netw. 2022. PMID: 35830888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

647 results

Search Page